JPH08508034A - フェノキシフェニル酢酸誘導体 - Google Patents

フェノキシフェニル酢酸誘導体

Info

Publication number
JPH08508034A
JPH08508034A JP6521226A JP52122694A JPH08508034A JP H08508034 A JPH08508034 A JP H08508034A JP 6521226 A JP6521226 A JP 6521226A JP 52122694 A JP52122694 A JP 52122694A JP H08508034 A JPH08508034 A JP H08508034A
Authority
JP
Japan
Prior art keywords
alkyl
coor
conr
unsubstituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP6521226A
Other languages
English (en)
Japanese (ja)
Inventor
バグリー，スコツト・ダブリユ
ブローテン，セオドア・ピー
チヤクラバーテイ，プレイスン・ケイ
デイノア，ダルジツト・エス
フイツチ，ケネス・ジエイ
グリーンリー，ウイリアム・ジエイ
ケビン，ナンシー・ジヨー
ペテイボーン，ダグラス・ジエイ
リベロ，ラルフ・エイ
タータ，ジエイムズ・アール
ウオルシユ，トーマス・エフ
ウイリアムズ，デイビツド・エル・ジユニア
Original Assignee
メルク エンド カンパニー インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク エンド カンパニー インコーポレーテッド filed Critical メルク エンド カンパニー インコーポレーテッド
Publication of JPH08508034A publication Critical patent/JPH08508034A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP6521226A 1993-03-19 1994-03-17 フェノキシフェニル酢酸誘導体 Withdrawn JPH08508034A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3445593A 1993-03-19 1993-03-19
US034,455 1993-03-19
US19746794A 1994-02-24 1994-02-24
US197,467 1994-02-24
PCT/US1994/002871 WO1994021590A1 (fr) 1993-03-19 1994-03-17 Derives d'acide phenoxyphenylacetique

Publications (1)

Publication Number Publication Date
JPH08508034A true JPH08508034A (ja) 1996-08-27

Family

ID=26710968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6521226A Withdrawn JPH08508034A (ja) 1993-03-19 1994-03-17 フェノキシフェニル酢酸誘導体

Country Status (23)

Country Link
EP (1) EP0617001B1 (fr)
JP (1) JPH08508034A (fr)
KR (1) KR960700992A (fr)
CN (1) CN1119434A (fr)
AT (1) ATE189217T1 (fr)
AU (1) AU679710B2 (fr)
CA (1) CA2119051A1 (fr)
CZ (1) CZ233595A3 (fr)
DE (1) DE69422742T2 (fr)
DK (1) DK0617001T3 (fr)
ES (1) ES2141197T3 (fr)
FI (1) FI954404A (fr)
GR (1) GR3032643T3 (fr)
HR (1) HRP940179B1 (fr)
HU (1) HU217028B (fr)
IL (1) IL108944A0 (fr)
NO (1) NO953672L (fr)
NZ (1) NZ263414A (fr)
PL (1) PL175786B1 (fr)
PT (1) PT617001E (fr)
RU (1) RU2139273C1 (fr)
SK (1) SK114795A3 (fr)
WO (1) WO1994021590A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520858A (ja) * 2002-03-20 2005-07-14 メタボレックス， インコーポレイテッド 置換フェニル酢酸
JP2012046531A (ja) * 1997-09-26 2012-03-08 Abbott Gmbh & Co Kg 医薬組合せ剤

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124343A (en) * 1919-01-27 2000-09-26 Rhone-Poulenc Rorer Limited Substituted phenyl compounds with a substituent having a thienyl ring
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO1996004905A1 (fr) * 1994-08-08 1996-02-22 Merck & Co., Inc. Derives de l'acide phenoxyphenylacetique
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
NZ298853A (en) * 1995-01-27 1998-07-28 Rhone Poulenc Rorer Ltd 5-[2-cyano-phenoxy]-2-phenyl-acetic acid derivatives
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
DE19527568A1 (de) * 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CA2238976A1 (fr) * 1995-12-12 1997-06-19 Merck & Co., Inc. Procede relatif a la fabrication d'un antagoniste de l'endotheline
US5688974A (en) * 1995-12-12 1997-11-18 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
ES2241036T3 (es) * 1996-02-02 2005-10-16 MERCK & CO., INC. Procedimiento de tratamiento de diabetes y estados patologicos asociados.
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CN1211183A (zh) 1996-02-20 1999-03-17 布里斯托尔-迈尔斯斯奎布公司 联苯基异噁唑磺酰胺的制备方法
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
GB9609641D0 (en) * 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19710831A1 (de) * 1997-03-15 1998-09-17 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
GB9722287D0 (en) * 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
DE19747788A1 (de) 1997-10-29 1999-05-06 Basf Ag Substituierte 2-(2'-Pyridyloxy)phenylessigsäureamide, ihre Herstellung und Verwendung, sowie sie enthaltende Mittel
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
WO1999048530A1 (fr) * 1998-03-23 1999-09-30 Merck & Co., Inc. Therapie combinee pour le traitement de l'hyperplasie prostatique benigne
CA2326427A1 (fr) 1998-03-31 1999-10-07 Koichiro Yamada Agents prophylactiques/therapeutiques contre les troubles urinaires
US6017918A (en) * 1998-08-06 2000-01-25 Warner-Lambert Company Phenyl glycine compounds and methods of treating atherosclerosis and restenosis
US6284795B1 (en) 1998-09-04 2001-09-04 Warner-Lambert Company Sulfonamide compounds and methods of treating atherosclerosis and restenosis
EP1165472A4 (fr) 1999-03-19 2002-11-20 Bristol Myers Squibb Co Procedes pour la preparation de diphenylisoxazolesulfonamides
WO2001027077A2 (fr) * 1999-10-12 2001-04-19 Basf Aktiengesellschaft Procede d'identification d'inhibiteurs de cdc25
EP1330444B1 (fr) 2000-11-01 2011-03-23 Millennium Pharmaceuticals, Inc. Composes heterocycliques azotes et leur procede de fabrication
EP1366012A4 (fr) 2001-02-09 2005-11-02 Merck & Co Inc Acides 2-aryloxy-2-arylalcano ques utilis s pour le traitement du diab tes et des troubles lipidiques
US8614236B2 (en) 2006-12-12 2013-12-24 University Of Washington Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
CN101042381B (zh) * 2007-04-28 2014-01-08 长春迈灵生物工程有限公司 一种地舍平的检测方法
WO2011056126A1 (fr) * 2009-11-09 2011-05-12 Novadex Pharmaceuticals Ab Nouveaux composés de 1,3-oxazolidine et utilisation de ces derniers comme inhibiteurs de la rénine
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
WO2012007877A2 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
WO2012007883A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composés chimiques
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
CN104744370A (zh) 2011-02-08 2015-07-01 辉瑞大药厂 胰高血糖素受体调节剂
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
CN111825564B (zh) * 2020-09-21 2020-12-29 西藏甘露藏药股份有限公司 一种从渣驯中提取的化合物、制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1408738A (fr) * 1964-04-29 1965-08-20 Nobel Bozel Nouveaux dérivés de l'acide bis(hydroxy-4-phényl)-acétique
US4748272A (en) * 1986-08-01 1988-05-31 Rorer Pharmaceutical Corp. Phenoxyphenylacetates for use as potential modulators of arichidonic acid pathways
JPS63122605A (ja) * 1986-11-10 1988-05-26 Tokuyama Soda Co Ltd 除草剤組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012046531A (ja) * 1997-09-26 2012-03-08 Abbott Gmbh & Co Kg 医薬組合せ剤
JP2005520858A (ja) * 2002-03-20 2005-07-14 メタボレックス， インコーポレイテッド 置換フェニル酢酸

Also Published As

Publication number Publication date
AU5787894A (en) 1994-09-22
AU679710B2 (en) 1997-07-10
NO953672D0 (no) 1995-09-18
WO1994021590A1 (fr) 1994-09-29
FI954404A0 (fi) 1995-09-18
IL108944A0 (en) 1994-06-24
NZ263414A (en) 1997-09-22
EP0617001B1 (fr) 2000-01-26
RU2139273C1 (ru) 1999-10-10
ATE189217T1 (de) 2000-02-15
DK0617001T3 (da) 2000-04-17
SK114795A3 (en) 1996-06-05
HRP940179B1 (en) 2000-10-31
CZ233595A3 (en) 1996-01-17
HRP940179A2 (en) 1998-02-28
DE69422742D1 (de) 2000-03-02
CN1119434A (zh) 1996-03-27
HU217028B (hu) 1999-11-29
KR960700992A (ko) 1996-02-24
PL175786B1 (pl) 1999-02-26
GR3032643T3 (en) 2000-06-30
PL310661A1 (en) 1995-12-27
FI954404A (fi) 1995-09-18
HU9502725D0 (en) 1995-11-28
EP0617001A1 (fr) 1994-09-28
ES2141197T3 (es) 2000-03-16
PT617001E (pt) 2000-06-30
CA2119051A1 (fr) 1994-09-20
DE69422742T2 (de) 2000-08-17
HUT73658A (en) 1996-09-30
NO953672L (no) 1995-11-17

Similar Documents

Publication Publication Date Title
JPH08508034A (ja) フェノキシフェニル酢酸誘導体
US5668176A (en) Phenoxyphenylacetic acid derivatives
US5538991A (en) Endothelin antagonists bearing 5-membered heterocyclic amides
JP5616326B2 (ja) Ｆｘｒのモジュレーターとしてのベンゾフラン、ベンゾチオフェン、ベンゾチアゾール誘導体
WO1996009818A1 (fr) Antagonistes du recepteur d'endotheline utilises dans le traitement des vomissements
JP2000517297A (ja) Ｍｍｐとｔｎｆの抑制活性を有するヒドロキサム酸誘導体およびカルボン酸誘導体
US5559135A (en) Endothelin antagonists bearing pyridyl amides
CA2651128A1 (fr) Modulateurs des recepteurs vr1 derives du benzimidazole
JP2015522597A (ja) 新規の５−アミノテトラヒドロキノリン−２−カルボン酸およびその使用
TW200521108A (en) Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
KR20090122931A (ko) 오르니틴 유도체
RU2232751C2 (ru) Производные сульфонамидов и фармацевтическая композиция
US5686478A (en) Endothelin antagonists
JPH10503779A (ja) フェノキシフェニル酢酸誘導体
JP2000515501A (ja) 低血糖化および低脂血化用化合物群
JP2005539005A (ja) ヘパラナーゼ阻害物質としてのフランチアゾール誘導体
HUT70512A (en) Benzenealkanoic acid, pharmaceutical compns. contg. them and process to prepare the said compds
US5767310A (en) Phenoxyphenylacetic acid derivatives
AU705881B2 (en) Phenoxyphenylacetic acid derivatives
WO2021118826A1 (fr) Acides phénoxyphényl acétiques substitués enrichis en deutérium et acylsulfonamides
RU2431480C2 (ru) Сложноэфирные производные и их медицинское применение
JPH09249628A (ja) フェノール誘導体

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20031204